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Abstract
Aberrantly activated kinase signaling pathways drive invasion and dissemination in medulloblastoma (MB). A majority of tumor-
promoting kinase signaling pathways feed into the mitogen-activated protein kinase (MAPK) extracellular regulated kinase (ERK1/2)
pathway. The activation status of ERK1/2 during invasion of MB cells is not known and its implication in invasion control unclear.
We established a synthetic kinase activation relocation sensor (SKARS) for the MAPK ERK1/2 pathway in MB cells for real-time
measuring of drug response. We used 3D invasion assays and organotypic cerebellum slice culture to test drug effects in a physio-
logically relevant tissue environment.
We found that hepatocyte growth factor (HGF), epidermal growth factor (EGF), or basic fibroblast growth factor (bFGF) caused
rapid nuclear ERK1/2 activation in MB cells, which persisted for several hours. Concomitant treatment with the BCR/ABL kinase
inhibitor dasatinib completely repressed nuclear ERK1/2 activity induced by HGF and EGF but not by bFGF. Increased nuclear
ERK1/2 activity correlated positively with speed of invasion. Dasatinib blocked ERK-associated invasion in the majority of cells, but
we also observed fast-invading cells with low ERK1/2 activity. These ERK1/2-low, fast-moving cells displayed a rounded morphol-
ogy, while ERK-high fast-moving cells displayed a mesenchymal morphology. Dasatinib effectively blocked EGF-induced prolifer-
ation while it only moderately repressed tissue invasion, indicating that a subset of cells may evade invasion repression by dasatinib
through non-mesenchymal motility. Thus, growth factor-induced nuclear activation of ERK1/2 is associated with mesenchymal
motility and proliferation in MB cells and can be blocked with the BCR/ABL kinase inhibitor dasatinib.
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Introduction
The mitogen-activated protein kinase (MAPK) signaling pathways are
evolutionary conserved signaling modules leading to the activation of
either extracellular regulated kinases (ERKs), p38 activated kinase or
c-jun N-terminal kinase (JNK). MAPK signaling is induced by
extracellular cues and transmitted through a tier of sequentially activated
receptors, adaptor proteins, small GTPases and kinases that control differ-
entiation, proliferation, viability and migration of cells and tissues. Aberrant
activation of MAPK signaling, for example by the amplification of a
pathway-inducing receptor, by the mutational alterations of receptors or
signal-transmitting intermediates or by the inactivation of pathway repres-
sors is observed inmultiple tumors including medulloblastoma (MB) [1–6],
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the most common malignant brain tumor in children. Molecular profiling
of MB defined four subgroups with a total of 12 subtypes [7,8], with vari-
able demographic, clinical andmolecular features [9]. The large heterogene-
ity of MB tumors underscores the necessity to identify those MB tumors
potentially susceptible to MAPK-ERK1/2 inhibition. With CD271 [2]
and BMI1 [10] two such biomarkers were identified for sonic hedgehog
(SHH) and Group 4 (Gr4) MB tumors [9], respectively.
The regulated translocation of activated ERK1/2 into the nucleus
thereby constitutes a particular function of the pathway, as it causes the spa-
tial separation of the activated kinase and the phosphorylation of a selected
repertoire of substrates [11]. The C-terminal region and in particular amino
acids Asp-316, Asp-319 and Glu-320 were found to be required for nuclear
translocation [12], which is mediated by the phosphorylation-dependent
release of the cytosolic anchoring protein and shuttling via importin 7
[13,14]. The nuclear activation of ERK1/2 in cells and tissues and the func-
tional significance of spatio-temporal activation for normal and aberrant cell
function are incompletely understood. With new tools for real-time visual-
ization of nuclear ERK1/2 activities established, including ERK1/2-nKTR,
a genetically encoded biosensor for extracellular regulated kinase [15],
ERK1/2 activation patterns can now be tracked and correlated with cellular
functions. This sensor was further developed and adapted to themammalian
system for quantifying MAPK dynamics in living mammalian cells [16].
Direct repression of MAPKs MEK or ERK1/2 or the upstream activa-
tor Ras are associated with the emergence of resistance either by the reac-
tivation of ERK1/2 through impaired repression or the activation of an
alternative pathway [17–19]. One potential indirect repressor of
ERK1/2 activation in tumor cells is dasatinib, a second-generation multi-
target kinase inhibitor targeting both SRC and BCR-ABL kinases. It was
discovered as a small molecular inhibitor binding to ABL with less strin-
gent conformational requirements than Imatinib and shown to effectively
inhibit BCR/ABL-driven diseases [20]. Dasatinib is FDA-approved for the
treatment of chronic myeloid leukemia that is resistant to imatinib treat-
ment. Aberrant receptor tyrosine kinase (RTK) and SRC kinase signaling
are hallmarks of Gr4 medulloblastoma [21] and the activation of c-MET
[22–24] or FGFR [25] promotes migration and invasion in SHH and Gr4
MB tumor cells. EGF signals through HER2 and EGFR and blockade of
these receptors by gefitinib reduces MB tumor growth and invasion [6].
SRC is a downstream effector of these signaling pathways, and it was sug-
gested that dasatinib could be an effective inhibitor of RTK-driven MB
pathologies [21]. Indeed, an earlier study already described inhibitory
effects of dasatinib alone or in synergy with the aurora kinase inhibitor
AT9283 on cell migration and proliferation [26]. More recently, a combi-
natorial effect on MB tumor cell clonogenicity was observed after treat-
ments with dasatinib and cisplatin [27]. The aims of this study were to
test the efficacy of FDA-approved drugs in repressing HGF-induced inva-
sion of SHH MB cells, to monitor nuclear MAPK signaling in response to
growth factors in real-time and to determine whether drug repression of
invasiveness correlates with decreased nuclear MAPK activity.
Material and methods
Cell lines and reagents
The DAOY cell line was obtained from ATCC (HTB-186, authenti-
cated: June 15, 2018) and cultured in IMEM (A1048901, Thermo Fisher,
Waltham, MA, USA) as described in [28]. ONS-76 [29] were kindly pro-
vided by Xiaochong Wu, The SickKids, Toronto, and cultured in
DMEM. The culture medium was supplemented with FBS (10%) and
penicillin/streptomycin (1%). Serum-free medium (SFM) is IMEM, sup-
plemented with penicillin/streptomycin (1%). The pMM55_pLV-CMV-
MEK2-2NLS-mClover plasmid [16] for CMV-driven ERK Synthetic
Kinase Activation Relocation Sensor (ESKARS) expression was provided
by M. Ma. Infectious lentiviral particles of rLV.EF1.mCherry-Nuc-9 for
nuclear expression of mCherry were purchased from Takara Bio Inc.
(Kusatsu, Japan). Stable ESKARS and m-Cherry-nuc expressing DAOY
cells were generated by lentiviral transduction. ESKARS encoding
VSVG-coated lentivirus was generated by transfection of HEK-293T cells
with the lentiviral packaging vectors pPax2, pVSVG and pMM55_
pLV-CMV-MEK2-2NLS-mClover (4.5:3.0:7.5). Virus supernatant was
harvested 30 h after transfection and target cells were transduced in the
presence of polybrene (1:1,000). Stable cell lines were selected with puro-
mycin [2 mg/ml] (rLV.EF1.mCherry-Nuc-9) or blasticidin [4 mg/ml]
(pMM55_pLV-CMV-MEK2-2NLS-mClover). DAOY LA-EGFP cells
were produced by lentiviral transduction of DAOY cells with pLenti-
LA-EGFP [24].
Growth factors, drugs and concentrations used
HGF: 20 ng/ml, EGF: 30 ng/ml, bFGF: 100 ng/ml (all from Prepro-
tech). Drugs: (all from Selleckchem, Pittsburg, PA, USA): SCH772984:
1 mM, Staurosporin: 1 mM, H2O2: 800 mM. Axitinib: 1 mM, 5 mM,
10 mM, NPV-BEZ35: 250 nM, 500 nM, 1 mM, 5 mM, 10 mM, dasatinib
(BMS-354825): 250 nM, 1 mM, 5 mM, 10 mM, Erlotinib HCI: 250 nM,
500 nM, 1 mM, 5 mM, 10 mM, Imatinib mesylate: 1 mM, 5 mM, 10 mM,
Nilotinib (AMN-107): 1 mM, 5 mM, 10 mM, Rapamycin (sirolimus):
250 nM, 500 nM, 1 mM, 5 mM, 10 mM, Sunitinib malate (sutent):
1 mM, 5 mM, 10 mM, Temsirolimus (torisel): 1 mM, 5 mM, 10 mM, Masi-
tinib (AB1010): 500 nM, 1 mM, 5 mM, 10 mM, Crizotinib (PF-
02341066): 250 nM, 500 nM, 1 mM, 5 mM, 10 mM, Foretinib:
500 nM, 1 mM, 5 mM, 10 mM (Selleckchem), XL-184: 1 mM, 5 mM,
10 mM, Vermurafenib (PLX4032): 1 mM, 5 mM, 10 mM, Zoledronic acid
(zoledronate): 1 mM, 5 mM, 10 mM, Ruxolitinib (INCB018424):
500 nM, 1 mM, 5 mM, 10 mM, Nystatin (mycostatin): 1 mM, 5 mM,
10 mM, lapatinib: 1 mM, 5 mM, 10 mM, Pazopanib: 1 mM, 5 mM,
10 mM, dequalinium chloride: 1 mM, 5 mM, 10 mM, Tofacitinib citrate
(CP-690550 citrate): 500 nM, 1 mM, 5 mM, 10 mM. H-1152 (from
Alexis Biochemicals): 1 mM.
Spheroid invasion assay (SIA)
SIA was performed and quantified according to [30]. In brief: 2,000
cells were seeded in 100 ml complete medium per well in cell-repellent
96 well microplates (650790, Greiner Bio-One, Kremsmünster, Austria).
Cells were allowed to form spheroids for 24 h after which 70 ml medium
were removed and replaced with 70 ml of a mixture containing 3.65 ml
sodium bicarbonate (7.5%), 6.64 ml 10 DMEM and 59.71 ml PureCol
(3 mg/ml, CellSystems, Troisdorf, Germany). Polymerized collagen I
hydrogels were overlaid with 100 ml SFM containing growth factors and
inhibitors. Growth factor stimulation were performed with bFGF
(100 ng/ml), HGF (20 ng/ml) or EGF (30 ng/ml). Growth factors and
drugs were mixed in 2 concentration into the 100 ml SFM to reach
1 concentration in the final dilution. Cell dissemination was acquired
24 h post treatment with an AxioObserver wide-field microscope using
a 5 objective (Zeiss, Jena, Germany) and analyzed with our in-house cell
dissemination counter software aSDICs [30]. This software determines the
distance of each nucleus of the migrating cells to the center of the spher-
oid. Mean distance and total cumulated distance of invasion is quantified.
Confocal microscopy analysis of spheroids in collagen I
Tumor cell spheroids were grown as described above for the SIA. Glass
bottom 96 well plates (Cellvis, P96-1.5H-N) were made low adhesive
using Lipidure (0.5% in EtOH, 20 ml of a 5 mg/ml solution per well).
Plate with Lipidure was placed on a horizontal shaker for 10 min and then
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maintained at room temperature until EtOH was evaporated. Spheroids
were transferred into these pretreated plates and embedded in collagen
I. Spheroids were left untreated or treated with the following conditions:
EGF 30 ng/ml, dasatinib 250 nM, H-1152 1 mM, EGF + dasatinib, EGF
+ H-1152, EGF + dasatinib + H-1152. After 16 h, cells were fixed in 4%
PFA and nuclei labeled with Hoechst 33342, 1:5000 dilution. Images
were acquired with a 20 immersion objective on a Leica SP8 confocal
microscope. 1024  1024 pixels image stacks with 1 mm Z-distance from
the whole spheroid or single cells were acquired.
Cell-Tox green cytotoxicity assay
i96 well plates
2500 ONS-76 cells were seeded in 100 ml per well of complete RPMI
medium in 96-well low adhesion plate (Greiner bio-one, 650970, Ger-
many) for 24 h to form spheroids. After spheroid formation, 50 ml of med-
ium per well were removed and replaced by 50 ml fresh medium
containing increasing concentrations of drugs, complemented with
1:500 of CellTox™ Green Dye (G8742, Promega) as described by the
manufacturer. The fluorescence levels representing the nonviable cell pop-
ulation were measured after 24, 48 and 72 h using a Cytation 3 imaging
reader BioTek (kex = 485 nm, kem = 520 nm). The cytotoxicity curve
was generated with GraphPad Prism 8 software as log (inhibitor) vs.
response  Variable slope (four parameters) with 100% as the effect
observed with the highest concentration of dasatinib (80 mM).
i384 well plates
250 DAOY cells in 20 ll per well were seeded in a 384 well Corning
spheroid microplate (Corning Incorporated, NY, USA). After 24–48 h,
FDA-approved drugs were dispensed with a hp d300 digital dispenser in
three different concentrations. Staurosporin (250 nM, 500 nM, 1 mM
and 2 mM) and H2O2 (800 mM) were used as positive controls. After
24 h, cell tox green was added (20 ml per well). After an incubation time
of 15 min at room temperature and protected from light, the fluorescence
signal was measured using a Cytation 3 imaging reader BioTek
(kex = 485 nm, kem = 520 nm.
WST-1 cell proliferation assay, DAOY cells
1,000 cells were seeded in 100 ml complete IMEM in 96-well plates
(Greiner mClear). Wells lining the borders of the plate were filled with
PBS. The plates were incubated for 24, 48, 72, or 96 h. After addition
of 10 ml WST-1 (Roche Diagnostics) reagent, cells were incubated at
37 C for 30 min before absorbance was measured at 440 nm using a
microplate reader. Medium containing GFs and inhibitors was changed
daily. For each condition, a blank measurement pas performed for back-
ground subtraction. Data analysis was performed using GraphPad Prism 7.
ESKARS analysis two-dimensional (2D) system
5,000 cells were seeded in a 96-well plate (Greiner mClear) in 100 ml
complete medium. After 6 h, the complete medium was replaced with
starvation medium and cells were incubated overnight at 37 C. After star-
vation, growth factors and inhibitors were added individually, and plates
sealed with a gas-permeable membrane. Image acquisition was started
1 min after treatment using a Molecular Devices ImageXpressMICRO
equipped with a 20 objective and a climate chamber with temperature
and CO2 control. Cells were imaged with an exposure time of 25–
35 ms, using either the 531 nm (mCherry-nuc-9) or 482 nm (ESKARS)
wavelengths. The interval time between acquisitions was 60 s and duration
of image acquisition between 5 and 240 min. Video files were converted
into image sequences using ImageJ (version 1.51 g) and channels separated
into gray-scale images using CellProfiler (version 2.2.0). Nuclei were iden-
tified using the mCherry-nuc-9 fluorescence and defined as primary
objects. Primary objects outside the set diameter range of 40–80 pixels
or touching an edge of the image were excluded. Primary objects were
used as masks to mark the nuclear boundaries and to track single cells.
The maximum gap distance between objects per interval was set to 50 pix-
els. Pixel intensities in the cytoplasmic compartment were quantified by
expanding the primary objects by 70 pixels, which resulted in a circular
mask surrounding the primary object. This mask was applied to the green
channel (ESKARS fluorescence) for the quantification of the cytoplasmic
pixel intensities. Data processing and visualization were performed in R
and GraphPad Prism 7, respectively.
ESKARS analysis in three-dimensional (3D) matrix
Spheroids were generated as described for the SIA. Single spheroids
were transferred in 9 ml medium into separate wells of 15-well Angiogen-
esis slides (ibidi, Martinsried, Germany). Subsequently, 21 ml of a 2.5%
PureCol solution was added to each well. After polymerization at 37 C,
growth factors and inhibitors were added dropwise to the wells. The
images were acquired using a CLSM-Leica SP8 confocal microscope
equipped with temperature- and CO2-controlled stage and a 10 objec-
tive. Total acquisition time was 24 h with time intervals of 10 min. For-
mat 1024  1024, speed 8000 (with resonant scanner), bidirectional
on, zoom factor 1.7, line average 64, number of steps: 15, Z-step size
5.0 mm.
The exported video files were further processed using Imaris (version
9.2.0). mCherry-nuc-9 fluorescence was determined as a mask for delin-
eating the area of the nuclei and used to measure the mean intensity of
the ESKARS fluorescence within the nucleus. Digital thresholding was
performed using Imaris. The background was subtracted at the value of
23.8112 and the diameter of the largest sphere was determined as
5.02 mm. The surface grain size was set to 1.34 mm and only objects con-
taining more than 100 voxels were included. Autoregressive motion was
applied for nuclei tracking with the maximal distance covered between
two intervals set to 14.5 mm. The maximal gap size was defined as 3
and the filling of gaps was enabled. For the analysis, only tracks with a
duration longer than 2000 s were included
Single cell motility analysis
5000 cells DAOY-LA-EGFP per well in 200 ml medium with 1.5%
FBS were seeded on collagen IV-coated 8-well slides (ibidi, Martinsried,
Germany). After 4 h, EGF (30 ng/ml) or bFGF (100 ng/ml) or EGF
+ 250 nM dasatinib or bFGF + 250 nM dasatinib were added in 100 ml
SFM (final FBS concentration: 1%). Time-lapse imaging was performed
with a widefield Nikon Eclipse Ti2 inverted microscope equipped with
temperature and CO2-controlled stage incubation system. Images were
recorded in EGFP channel using a 20 dry objective in 15 min intervals.
Total acquisition time was 18 h. Images were assembled in .avi movie and
analyzed in Fiji (ImageJ [31]). .avi movies were converted to gray scale and
brightness/contrast adjusted so that also weakly LA-EGFP-positive cells
were detected. Images were thresholded and threshold applied to whole
image stack. Images were then converted into binary images. Tracking
was performed using the MtTrack2 plugin (Object size: 60, max object
size: 800, maximum velocity: 100, minimum track length: 50). Speed
in mm/min and directionality (displacement:path length) was calculated
for all recorded cells and plotted as violin plots in prism.
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Data rearrangement and statistical analysis
The rearrangement of the different data sets was performed using R
(versions 3.5.1 and 3.5.2) and RStudio (version 0.99.903). Statistical anal-
ysis was performed using GraphPad Prism (versions 7 and 8).
Ex vivo organotypic cerebellum slice culture (OCSC)
Cerebellar slices were prepared form P8-10 C57BL/6JRj mouse pups
as described in [32]. Slices were kept in culture for 15 days, during which
we monitored sliced for signs of apoptosis. We changed the media daily.
Tumor spheroids were formed with DAOY LA-EGFP cells. The co-
culture was treated with EGF (30 ng/ml), dasatinib (250 nM) or the com-
bination of the two treatments. Spheroids were incubated for 5 days. Fol-
lowing the treatment, the co-cultures were fixed and stained as described
in [32] and analyzed using confocal immunofluorescence microscopy.
Results
Dasatinib blocks collagen invasion and proliferation of SHH MB cell
lines
In a search for FDA-approved kinase inhibitors (Fig. 1A) that repress
growth factor-induced collagen I invasion, we identified dasatinib as an
effective inhibitor of HGF-induced invasion in DAOY MB cells
(Fig. 1B). This effect of dasatinib was not the result of cytotoxicity, as
we observed no increase in cell death in cells treated with up to 10 mM
(Fig. 1C and 2C). To determine whether dasatinib also blocks invasion
induced by bFGF or EGF, we quantified growth factor-induced collagen
I invasion of tumor cell spheroids [30] in the presence of dasatinib
(Fig. 2A). Dasatinib effectively blocked collagen I invasion driven by the
three growth factors with an IC50 ranging from 9.44 nM (bFGF) to
38.28 nM (HGF) to 71.78 nM (EGF, Fig. 2B). Basal collagen I invasion
in the absence of growth factor stimulation was also blocked with a mod-
erately higher EC50 of 110.40 nM. Dasatinib and danusertib, another
BCR-ABL/SRC inhibitor, but not erlotinib, an EGFR inhibitor, effec-
tively blocked collagen I invasion of ONS-76, a SHH MB line that
invades collagen I gels under low serum condition independent of growth
factor stimulation (Fig. 2C). We calculated the IC50 of dasatinib in ONS-
76 cells as 3.95 nM and observed cytotoxicity only well above 10 mM drug
concentration (Fig. 2C). Dasatinib also markedly reduced the speed of
EGF- or bFGF-induced single cells migrating on collagen IV coated slides,
although a remarkable number of cells still migrated in the presence of
dasatinib (Fig. S1, M1 – M5). In the 3D migration analysis, 250 (bFGF),
500 (HGF) or 1000 (EGF) nM dasatinib was necessary to reduce growth
factor-induced collagen I invasion to baseline (Fig. S2). To determine the
impact of dasatinib treatment on proliferation and viability in DAOY cells,
we performed a WST-1 assay with increasing concentrations of dasatinib
in regular growth medium. No significant repression of proliferation was
observed up to 24 h of treatment for all concentrations tested. Exposure
to inhibitor concentrations up to 125 nM for 48 h caused marked repres-
sion of proliferation, and concentrations of 250 nM or higher almost com-
pletely abrogated proliferation (Fig. 2D). These data indicate that
migration and proliferation of MB cells can be effectively blocked by dasa-
tinib at nanomolar to low micromolar concentrations without the impli-
cation of cytotoxicity.
Dasatinib prevents nuclear ERK1/2 activity induced by growth factor
stimulation
The activation of the MAPK pathway is a hallmark signature of recep-
tor tyrosine kinase activation. The effector kinases of this layered signaling
pathway are the extracellular regulated kinases ERK1/2, p38 and JNKs.
Nuclear translocation of ERK1/2 is necessary for controlling nuclear sub-
strates and is associated with oncogenesis (reviewed in [11]). To determine
nuclear translocation dynamics of activated ERK1/2 in real time in living
MB cells, we established the SKARS [16] biosensor for ERK1/2 in DAOY
MB cells (DAOY-ESKARS, Fig. S3). To test sensor functionality, we
stimulated DAOY-ESKARS cells with EGF and monitored translocation
of the biosensor. Nuclear fluorescence – indicative for lack of nuclear
ERK1/2 activity – was observed in starved cells. EGF stimulation caused
rapid translocation of the sensor to the cytoplasm, with a concomitant
increase of the cytoplasm:nucleus ratio (Fig. 3A). We tested the effect of
EGF, HGF and bFGF on sensor translocation over a period of 2 h. As
a control for specific translocation repression, we treated the cells with
the ERK1/2 inhibitor SCH772984. We found that all three growth fac-
tors caused rapid and sustained sensor translocation, which indicates
nuclear ERK1/2 activation (Fig. 3B). Pharmacological inhibition of
ERK1/2 kinase activity abrogated sensor translocation, thus confirming
that latter depends on active ERK1/2. ERK1/2 sensor activity returns
rapidly to baseline after GF wash-out and remains low in the presence
of SCH772984, demonstrating that sensor response is fast and reversible.
To test whether dasatinib can block growth factor induced nuclear
ERK1/2 activity, we compared cytoplasm:nucleus ratio in cells treated
with the growth factors or with growth factors in combination with dasa-
tinib. HGF- and EGF-induced nuclear ERK1/2 activity started to decrease
and reached baseline within 1 h of dasatinib treatment and remained at
baseline levels for the whole observation period of 3.5 h (Fig. 3C). In con-
trast, bFGF-induced nuclear ERK1/2 activity was only moderately
repressed and repression did not reach baseline levels throughout the
whole observation period. These data show that HGF- and EGF-
induced nuclear ERK1/2 activation is completely repressed by dasatinib,
whereas bFGF-induced nuclear ERK1/2 activation is incompletely
repressed and thus partially independent of the kinases inhibited by
dasatinib.
ERK1/2 is active in the nucleus of invading cells
Although pharmacological or genetic inhibition of ERK1/2 repressed
growth factor-induced collagen I invasion [25], it is not known whether
invasion correlates positively with increased nuclear ERK1/2 activity. To
test whether nuclear ERK1/2 activity could be required for invasive motil-
ity, we determined the ratio of nuclear to cytoplasmatic ESKARS fluores-
cence in cells invading the collagen I matrix. Within ten hours, we
observed invasive protrusions and invading cells in unstimulated cells in
serum-free medium (Fig. 4A, M6). Dasatinib treatment under these con-
ditions completely blocked invasion and invasive protrusion (M7). In
addition, we observed the appearance of cell debris in the immediate vicin-
ity of the spheroid (Fig. 4A, arrowheads), indicative for cell death. EGF
stimulation triggered massive collagen I invasion (Fig. 4B, left, M8), which
was largely but not completely blocked by dasatinib treatment (Fig. 4B,
right, M9). In contrast to dasatinib-treated control spheroids without
serum or growth factor (M7), we observed no cellular debris in
dasatinib-treated spheroids co-stimulated with EGF (M9). HGF (M10)
and bFGF (M12) also induced massive collagen I invasion whereby the
pattern of HGF-induced invasion is different (Fig. 4A), with overall fewer
invading cells and proportionally more cells invading as single cells with no
evident cell–cell contact. In the presence of dasatinib, neither HGF (M11)
nor bFGF (M13) stimulation did prevent the appearance of cell debris
(Fig. 4A). Using ESKARS, we quantified nuclear ERK1/2 activity in the
cells during collagen I invasion, to determine whether speed of migration
in collagen I correlated positively with nuclear ERK1/2 activity. To do
that, we grouped the cells according to speed in slow (low 25 percentile),
intermediate (interquartile range) and fast (top 25 percentile) moving cells
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(Fig. 5A). We then determined the nuclear ERK1/2 activity based on the
levels of nuclear ESKARS fluorescence, whereby low mean pixel intensity
indicates high ERK1/2 activity (Fig. 5B). We performed this for all
migrating cells in the absence and presence of growth factors (bFGF,
HGF or EGF) and without or with dasatinib (Fig. 5C, S4A). We observed
that fast-moving cells generally displayed a decreased, and slow-moving
cells an increased nuclear ESKARS fluorescence intensity. This indicated
that cell speed in the three-dimensional collagen matrix correlates posi-
tively with nuclear ERK1/2 activity (Fig. 5C, S4A). Dasatinib treatment
reduced the total number of migrating cells (Fig. 4A). The majority of
the remaining fast-moving cells still displaced high nuclear ERK1/2 activ-
ity (Fig. 5C, S4A). However, some very fast-moving cells displayed pro-
nounced nuclear ESKARS fluorescence, indicative of very low nuclear
ERK1/2 activity. bFGF or EGF stimulation significantly increased the
percentage of fast-moving cells with low nuclear ERK activity (Fig. 5D).
The fast-moving, low nuclear ERK1/2 cells migrated less directionally
(Fig. S4B) and displayed a rounded morphology (M9), contrasting with
the mesenchymal, elongated morphology observed in control cells. Thus,
growth factor stimulation triggers nuclear ERK1/2 activity, which is asso-
ciated with increased migration inside the 3D collagen I matrix. Dasatinib
represses nuclear ERK1/2 activation and significantly reduces 3D migra-
tion. Activated growth factor signaling in the presence of dasatinb also
Fig. 1. Identification of dasatinib as a non-toxic invasion inhibitor. (A) List of FDA-approved kinase inhibitors, concentrations used and predicted
targets. (B) Spheroid invasion assay (SIA) comparing the inhibitory effects of the kinase inhibitors at the indicated concentrations in the presence of HGF.
Each dot represents the distance in pixel of a single cell from the center of the spheroid. (C) CellTox green cytotoxicity assay to test the viability of tumor
cell spheroids exposed to the indicated concentrations of drugs for 24 h. H2O2 and staurosporin were used as positive controls.
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Fig. 2. Dasatinib blocks growth factor-induced collagen I invasion at nanomolar concentration. (A) Representative images of spheroid invasion assay (SIA)
after the treatment of DAOY cell spheroids with growth factors only (top row) and in combination with dasatinib (3 mM, bottom row) for 24 h. (B) IC50
curves of dasatinib dose response effect on growth factor-induced collagen I invasion in DAOY cells. IC50: Control = 110.40 nM, bFGF = 9.44 nM,
EGF = 71.78 nM, HGF = 38.28 nM. (C) Impact of Dasatinib, Danusertib or Erlotinib, all at 3 mM, on collagen I invasion of the spontaneously invading
SHH line ONS-76. Left: Representative images and corresponding quantification of triplicate measurements of mean distance of invasion. Middle: IC50
curve of dasatinib dose response effect on distance of invasion from collagen I-embedded ONS-76 spheroids. Right: CellTox green assay with ONS-76
tumor spheroids exposed to increasing concentrations of dasatinib. (D) WST assay to assess effect of increasing concentrations of dasatinib on DAOY cell
proliferation and viability. Comparison of low (0.0039–125 nM, left graph) and high (250–4000 nM, right graph) concentrations of dasatinib on DAOY
cells cultured in complete medium. The cells treated with 0.0039 nM of dasatinib were used as control condition (light green line).
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Fig. 3. Fast induction of SKARS translocation upon growth factor treatment. (A) Representative microscopy images of DAOY-ESKARS cells at timepoint 0
and 10 min post treatment with growth factors (top) and quantification of the ERK1/2 activity depicted as ratio of cytoplasmic fluorescence intensity to
nuclear fluorescence intensity (bottom). (B) Quantification of real-time ERK1/2 activity measurements. The graphs show the measurement of the nuclear
ERK1/2 activity as ratio of cytoplasmic:nuclear ESKARS after GF wash-out followed by treatment with either 1 mM ERK1/2 inhibitor SCH772984 (GF I
SCH772984) or GF (GF I GF), or GF plus SCH772984 (GF + SCH772984 I GF + SCH772984) GF concentrations used: EGF (30 ng/ml), HGF (20 ng/
ml) and bFGF (100 ng/ml). Dark lines: average, light-colored adjacent area: 95% confidence intervals. (C) Quantification of ERK1/2 sensor activation upon
treatment with SCH772984 (baseline), with growth factors (GF) and with growth factors combined with 250 nM dasatinib (GF + dasatinib).
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Fig. 4. Increased ERK1/2 activity in rapidly invading cells. (A) Inverted gray scale images of mClover fluorescence of collagen I-invading DAOY-
ESKARS cells under growth factor treatments as indicated and without or with 250 nM dasatinib. Time points T0 h and T10 h are shown. Red squares
indicate edges of spheroids and 2 magnifications thereof under dasatinib treatment for 10 h. (B) Snapshots of time-lapse imaging of EGF-induced
collagen I invasion of DAOY-ESKARS cells in the absence of and presence of 250 nM dasatinib (M8 and M9). The left columns of each condition
display still images of the overlaid green (mClover SKARS) and red (mCherry-nuc-9) channels at T0, T8, T16 and T24h. The right columns show the
corresponding intensity measurements and analysis. The mean intensities are visualized in a scale from 0 to 250 and color-coded from red (low ERK1/2
activity) to blue (high ERK1/2 activity). The speed of the cells is visualized by dragon tails in a scale from 0 to 0.03 mm/s color-coded also from red (slow)
to blue (fast). Scale bars microscopy pictures: 80 mm, scale bars analysis pictures: 100 mm. The area in the yellow boxes is magnified below the lowest
speed vector panels for better visualization.
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causes a subset of cells with low nuclear ERK1/2 activity to migrate rapidly
in a rounded motility mode (Fig. 5E). This suggests that dasatinib treat-
ment in the presence of activated growth factor receptors can promote
the activation of an alternative cell migration program in MB cells.
Dasatinib only partially represses EGF-induced tumor cell expansion
ex vivo
To explore the consequence of dasatinib treatment on tumor growth
and tissue infiltration, we assessed the impact of dasatinib treatment on
tumor expansion in organotypic cerebellum slice culture, which can be sig-
nificantly increased by EGF treatment [32]. We confirmed that EGF treat-
ment of cerebellar slices co-cultured with MB cells causes a marked
expansion of the tumor cells compared to control and results in massive
invasion of the tissue surrounding the spheroid (Fig. 6A). We also observed
a considerable increase in EDU-positive nuclei after EGF stimulation, sug-
gesting that EGF stimulation affects both proliferation and invasion. Co-
treatment with dasatinib caused only a small reduction of tumor cell inva-
sion distance (Fig. 6A, S5). However, we observed a considerable reduction
in EDU-positive nuclei in the tumor cells, suggesting that dasatinib caused
Fig. 5. High nuclear ERK1/2 correlates with high speed of migration. (A) The speed distribution across all cells measured is normally distributed. The
resulting Gaussian distribution curve can be separated in three phases, low quartile (Q1), median quartile (Inter Quartile Range, IQR) and high quartile
(Q4). (B) The mean pixel intensities (ESKARS fluorescence) in the nuclei of Q1 and Q4 cells treated /+ 30 ng/ml EGF and /+ 250 nM dasatinib
were collected and plotted against speed. High mean pixel intensities indicate low nuclear ERK1/2 activity, low mean pixel intensities high nuclear
ERK1/2 activity. (C) Mean pixel intensities in low (Q1, blue) and high (Q4, red) speed cells compared between unstimulated, EGF-stimulated and EGF
/+ dasatinib treatment. (D) Quantification of the percentage of dasatinib-treated cells with low nuclear ERK activity detected in the high-speed quartile
(Q4). (E) Schematic summary of dasatinib effect on ERK1/2 activity and motility mode in 2D (tissue culture dishes, slides) and in 3D (inside collagen I
matrices). The indicated effect of dasatinib on SRC kinases is based on literature information.
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complete repression of tumor cell proliferation after five days of treatment
(Fig. 6A, S5). In addition, closer inspection of the cells at the invasion front
revealed alterations in actin cytoskeleton morphology. Control and EGF-
treated cells displayed filamentous protrusions at the cell edges facing the
tissue environment (Fig. 6B, arrowheads). Dasatinib treatment in the
absence of EGF completely abrogated these structures. Instead, we
observed occasional bleb-like membrane extensions on cells near the inva-
sion front. Co-stimulation of slices with EGF and dasatinib partially res-
cued filopodia formation compared to dasatinib treatment alone. Thus,
although dasatinib treatment represses EGF-induced proliferation, it only
partially represses EGF-induced tissue invasion of MB tumor cells. The
reduction of filamentous F-actin assemblies in the cortex of the invading
cells suggests that dasatinib treatment in the presence of activated growth
factor receptors may shift the cell migration phenotype in a subset of cells
from mesenchymal to rounded motility mode in a tissue context as well.
ROCK inhibition is necessary for complete repression of EGF-induced
collagen I invasion
Rounded motility in cells treated with EGF and dasatinib indicated the
implication of Rho-Kinase (ROCK) in invasion control as was previously
shown for other invasive cancers in vitro and in vivo [33–35]. ROCK acti-
vation by TGF-Þ represses F-actin-rich filamentous protrusion formation
in MB cells in vitro and ex vivo, which can be reverted by treating the cells
with the ROCK inhibitor H-1152 [25]. H-1152 treatment of unstimu-
lated DAOY cells in collagen I gels causes a massive increase in filamen-
tous protrusions, which is in strong contrast to the complete repression
of filamentous protrusions in dasatinib-treated cells (Fig. 7A, S6). The
inhibition of SRC kinases by dasatinib causes membrane blebbing and
mesenchymal to amoeboid transition in melanoma cells embedded in col-
lagen I matrices [36]. We therefore tested whether rounded motility
observed in EGF-stimulated dasatinib-treated cells is prevented by ROCK
inhibition with H-1152. We found that dasatinib and H-1152 co-
treatment of EGF-stimulated DAOY cells reduced collagen I invasion
below levels measured for dasatinib treatment alone (Fig. 7B), suggesting
that the inhibition of both the SRC- and the ROCK-driven motility
modes is necessary for maximal repression of EGF-driven invasiveness.
Consistently, co-treatment of EGF-stimulated cells with dasatinib and
H-1152 caused complete disruption of F-actin structures and resulted in
a disorganized actin cytoskeleton (Fig. 7B). These data indicate that com-
bined inhibition of SRC-Rac and Rho-ROCK-driven F-actin polymeriza-
tion is necessary to prevent EGF-induced migration of MB cells in 3D
collagen I gels.
Discussion
In this study, we identified dasatinib as an effective inhibitor of growth
factor induced collagen I invasion. Repression of invasion by dasatinib is
associated with a marked reduction of nuclear ERK1/2 activity. In growth
factor-stimulated control cells, nuclear ERK1/2 activity is increased within
minutes, remains elevated for up to three hours and correlates positively
with speed of migration. Dasatinib treatment does not completely block
EGF-induced invasion and we observed cells with a rounded, blebbing
morphology and low nuclear ERK1/2 activity invading collagen gels.
Co-inhibition of Rho kinase ROCK is necessary for invasion inhibition
of these cells. Together, our data indicate that dasatinib is an effective inhi-
bitor of MAP kinase activation and cell migration downstream of growth
factor stimulation. However, its therapeutic potential needs careful evalu-
ation due to the onset of evading cells with a remarkable migratory poten-
tial that may need to be addressed with an inhibitor that specifically targets
cell contractility and rounded motility.
Cox regression and gene set enrichment analysis point towards a key
role of receptor tyrosine kinase-MAPK-ERK1/2 activation in the onset
and progression of MB, in particular of SHH, Gr3 and Gr4 MB [5].
Our data revealed that growth factor stimulation results in acute nuclear
ERK1/2 activation within minutes, which persists for at least two hours,
similar to what had been previously described for EGF-stimulated
ERK1/2-FRET biosensor activation [37]. Thus, unlike oncogenic activa-
tion of MAPK by mutant KRAS or BRAF, where feedback repression
of ERK1/2 by the dual-specific phosphatase 4 (DUSP4) prevents sus-
tained nuclear ERK1/2 activity [38], growth factor-stimulated ERK1/2
activity remains high in DAOY cells. Concomitant treatment with dasa-
tinib reduces nuclear ERK1/2 activity to baseline within one hour in cells
stimulated with EGF or HGF. Interestingly, in cells stimulated with
bFGF, dasatinib treatment did not lead to a complete repression of nuclear
ERK1/2 activity, suggesting a different regulation of nuclear ERK1/2 acti-
vation downstream of EGF and HGF compared to bFGF. One possibility
is an altered de-repression of the ERK1/2 inhibitor DUSP4 by the poly-
comb group protein B lymphoma Mo-MLV insertion region 1 homolog
(BMI), which promotes increased ERK1/2 activation and proliferation sig-
naling in Gr4 MB [10]. BMI1 expression is up-regulated by bFGF-FGFR
signaling in DAOY and the Gr3 MB line HD-MB03 [39], which may
explain incomplete dasatinib repression of nuclear ERK1/2 activity
through a BMI1-DUSP4-dependent mechanism.
Despite complete reduction of proliferation, we observed no effect of
dasatinib on viability of cells growing in the presence of 10% serum. How-
ever, reduction of the serum concentration to less than 2%, as for example
in the SIA, led to the appearance of debris around the spheroids. This sug-
gests that serum rescues the cells from undergoing cell death induced by
dasatinib. Cells are also rescued when stimulated with EGF but not when
stimulated with HGF or bFGF, indicating that either the signal strength
emanating from EGFRs or downstream effectors differ from those origi-
nating from c-Met or FGFR.
Dasatinib treatment of MB cells migrating in 2D on collagen-coated
coverslips causes a rounded phenotype and partial detachment. This is
most likely due to dasatinib inhibition of SRC family kinases, which are
necessary for focal adhesion formation and turnover [36]. Similarly, dasa-
tinib treatment of cells invading collagen I gels, a soft matrix triggering
mesenchymal, integrin-dependent migration of DAOY cells [40], caused
de-adhesion and cell rounding in other human tumor cells [36]. The pro-
cess of migration associated with cell rounding and blebbing in response to
de-adhesion and repression of pericellular proteolytic activity was referred
to as mesenchymal to amoeboid transition (MAT) [41,42]. Dasatinib
treatment of MB cells invading the brain tissue also results in cell round-
ing, the loss of F-actin-rich filamentous protrusions and bleb formation.
Unlike in 2D, the formation of filamentous protrusions is partially rescued
by EGF treatment, suggesting that the microenvironment of the brain tis-
sue provides additional cues favoring filopodia formation. In collagen I
matrix, where the ectopic growth factor and integrin activation provide
the migration cues, EGF stimulation of dasatinib-treated cells causes a par-
tial rescue of migration in a subset of cells, which migrate in a rounded,
blebbing mode. We explain this by the fact that integrin-mediated adhe-
sion signaling, which depends on SRC kinase activity [43], is lost in
dasatinib-treated cells. A consequence of de-adhesion is the disruption
and re-organization of the cortical action cytoskeleton and cell rounding,
which are both necessary for blebbing motility [34,35]. Consistent with
this possibility is our finding that blockade of cell rounding and blebbing
by the Rho-kinase ROCK inhibitor H-1152 also repressed migration of
this subset of cells. In EGFRwt/EGFRVIII glioblastoma multiforme
tumor cells, a similar compensatory migration mechanism induced by
dasatinib treatment was described recently, where the repression of ectopic
activation of SRC kinases increased cell velocity [44]. In addition to the
direct effect of EGF and dasatinib on the tumor cells, both treatments
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Fig. 6. Dasatinib causes only incomplete blockade of EGF-induced tissue invasion. (A) Top: Maximum intensity projections (MIP) of confocal sections
of OCSC with implanted DAOY tumor cell spheroids. Treatments as indicated. Green: LA-EGFP, blue: Purkinje cells. Middle: Inverted gray scale
images of MIP of LA-EGFP channel, lower: Inverted gray scale images of MIP of EDU staining. Scale bar corresponds to 100 mm. Magnification shows
inverted gray scale images of EDU-positive nuclei of host tissue (H) and tumor cells (T). Bar diagram shows mean and standard deviation (SD) of EDU-
positive nuclei in non-tumor and tumor cells. N = 2 experiments. (B) Magnification of invasion front of tumors shown in (A). Upper: Three color overlay
of maximum intensity projection. Green: LA-EGFP, blue: Purkinje cells, red: EDU-positive tumor cell nuclei. Middle: Gray scale images of LA-EGFP
channel. Arrowheads point to filamentous protrusions. Boxed areas are magnified 2 in bottom images. Scale bar corresponds to 10 mm.
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may also affect the tumor cell behavior indirectly via the modulation of the
microenvironment. One indication for EGF-dependent alterations in the
microenvironment is the increase in EDU-positive non-tumor cells in the
cerebellar slices.
The delivery of targeted therapies across the blood brain barrier
(BBB) challenges clinical translation of promising drugs. Indeed, the
brain penetration of dasatinib is poor, with a CSF:plasma ratio ranging
from 0.05 to 0.28. Nevertheless, dasatinib appears to be more potent
against CNS tumors than imatinib, possibly due to a much greater
potency of dasatinib and the large fraction of unbound drug [45].
Hence, coupling of dasatinib to av integrin-directed cRGD silica
nanoparticles, which facilitates drug passage across the partially disrupted
BBB in a murine GBM model, may be necessary for increasing the accu-
mulation, retention, and diffusion of the drug [46]. An alternative strat-
egy is convection-enhanced delivery of dasatinib in combination with the
ABC transporter inhibitor tariquidar and dexamethasone, which
enhanced tumor cell apoptosis and survival in a mouse model of
H3.3K27M mutant diffuse intrinsic pons glioma [47]. However, the
effect of dasatinib to promote a mesenchymal to amoeboid transition
in a subset of cells calls for cautious monitoring of therapeutic benefits,
in particular with respect to the consequence of drug treatment on local
infiltration at primary and metastatic sites.
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